Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. [electronic resource]
Producer: 20160606Description: 516-22 p. digitalISSN:- 1873-7560
- Adult
- Aged
- Aged, 80 and over
- Ambulatory Care -- economics
- Angiogenesis Inhibitors -- economics
- Antineoplastic Agents -- economics
- Bevacizumab -- economics
- Carcinoma, Renal Cell -- drug therapy
- Costs and Cost Analysis
- Denmark
- Drug Costs
- Efficiency
- Employment -- economics
- Everolimus -- economics
- Female
- Fluorouracil -- economics
- Health Care Costs
- Hospitalization -- economics
- Humans
- Immunologic Factors -- economics
- Indoles -- economics
- Interferon-alpha -- economics
- Interleukin-2 -- economics
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds -- economics
- Protein Kinase Inhibitors -- economics
- Pyrroles -- economics
- Radiography -- economics
- Radiotherapy -- economics
- Registries
- Sirolimus -- analogs & derivatives
- Sorafenib
- Sunitinib
No physical items for this record
Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.